公开(公告)号：US09884048B2

公开(公告)日：2018-02-06

申请号：US15531759

申请日：2015-12-10

申请人： Merck Sharp & Dohme Corp.

发明人： Phieng Siliphaivanh ,  Joey Methot ,  Kathryn Ann Lipford ,  Danielle Molinari ,  David L. Sloman ,  David Witter ,  Hua Zhou ,  Christopher Boyce ,  Xianhai Huang ,  Jongwon Lim ,  David Guerin ,  Ganesh Babu Karunakaran ,  Raman Kumar Bakshi ,  Ziping Liu ,  Jianmin Fu ,  Zhilong Wan ,  Wei Liu

IPC分类号： A61K31/437 ,  A61K31/4545 ,  A61K31/444 ,  C07D471/04 ,  C07D519/00

CPC分类号： A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  C07D471/04 ,  C07D519/00

摘要： The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

公开(公告)号：US20170266167A1

公开(公告)日：2017-09-21

申请号：US15531759

申请日：2015-12-10

申请人： Merck Sharp & Dohme Corp.

发明人： Phieng Siliphaivanh ,  Joey Methot ,  Kathryn Ann Lipford ,  Danielle Molinari ,  David L. Sloman ,  David Witter ,  Hua Zhou ,  Christopher Boyce ,  Xianhai Huang ,  Jongwon Lim ,  David Guerin ,  Ganesh Babu Karunakaran ,  Raman Kumar Bakshi ,  Ziping Liu ,  Jianmin Fu ,  Zhilong Wan ,  Wei Liu

IPC分类号： A61K31/437 ,  C07D519/00 ,  C07D471/04 ,  A61K31/4545 ,  A61K31/444

CPC分类号： A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  C07D471/04 ,  C07D519/00

摘要： The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

公开(公告)号：US09988397B2

公开(公告)日：2018-06-05

申请号：US15531771

申请日：2015-12-10

申请人： Merck Sharp & Dohme Corp. ,  MSD R&D (China) Co., Ltd.

发明人： Phieng Siliphaivanh ,  David L. Sloman ,  David Witter ,  Umar Faruk Mansoor ,  Joseph Kozlowski ,  Ziping Liu ,  Jianmin Fu ,  Zhilong Wan ,  Wei Liu ,  Yimin Qian ,  Xianhai Huang

IPC分类号： C07D498/18 ,  C07D471/18 ,  C07D471/22

CPC分类号： C07D498/18 ,  A61K31/437 ,  A61K31/444 ,  C07D471/18 ,  C07D471/22

摘要： The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a method of inhibiting ERK2 in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Formula (I). The invention also provides a method for treating cancer in a patient in need of such treatment, said method comprising administering to said patient an effective amount of at least one compound of Formula (I).